The Bulletin of Experimental Treatments for AIDS is your bright and brainy source on new developments in HIV prevention, evolving approaches to HIV treatment, and strategies for living well with the virus.
Sign up for our newsletter to get the latest info on HIV and AIDS:
In San Francisco, the sixth case of PrEP failure in a patient with high adherence was reported at IDWeek 2018 by Stephanie Cohen, MD, medical director of San Francisco City … Read More
Using PrEP for HIV prevention does not lower levels of feminizing hormones, and hormones only slightly reduce tenofovir levels, according to research presented at the International AIDS Conference in Amsterdam. These … Read More
I remember feeling confused and angry the first few times I was blocked or rejected by an online prospect who said they were on PrEP. I was confused, because—in every … Read More
The number of people using tenofovir/emtricitabine (Truvada) for PrEP exceeded 77,000 in 2016, according to new numbers from AIDSVu, released in conjunction with the 2018 Conference on Retroviruses and Opportunistic … Read More
Pre-exposure prophylaxis (PrEP) and other news about HIV transmission and prevention were among the tops stories at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI 2018) held in March … Read More
See more articles on the BETA Blog...